Paul Hermany, MD
Interventional Cardiology · Bethlehem, PANPI 1669784880
Payments from drug & device makers
Across 210 payments — averaging $310.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$47K
- Medtronic$11K
- Abbott$2K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Novartis$329
- plus $2K from 15 others
What the payments were for
- Grants$550%
- Travel & lodging$10,47658%
- Food & beverage$7,68342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 23 | $47,187 |
| Medtronic(2 entities) | 46 | $11,079 |
| Abbott | 15 | $2,074 |
| Edwards Lifesciences | 13 | $1,796 |
| Boston Scientific | 34 | $1,250 |
| Novartis | 27 | $329 |
| Abiomed | 9 | $316 |
| Shockwave Medical, Inc | 8 | $227 |
| Chiesi USA, Inc. | 3 | $190 |
| Pfizer | 7 | $168 |
| E.r. Squibb & Sons, L.L.C. | 8 | $150 |
| AstraZeneca | 4 | $145 |
| Cardinal Health 200 LLC | 1 | $117 |
| Boehringer Ingelheim | 2 | $57 |
| Johnson & Johnson | 2 | $36 |
| Terumo Medical Corporation | 2 | $29 |
| Lundbeck LLC | 2 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$9,695
- TRICLIP$1,481
- EVOQUE$823
- PASCAL$360
- MitraClip$290
- CoreValve Evolut$272
- Azure$250
- GENERAL - STENTS$249
- GORE CARDIOFORM Septal Occluder$170
- SAPIEN 3 Ultra RESILIA$166
- KENGREAL$156
- LINQ II$135
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- RESONATE$121
- GENERAL - STRUCTURAL HEART$114
- CareLink$106
How this compares
$65,232 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 318 | $396,508 |
| JardianceEmpagliflozin | 55 | $77,953 |
| EntrestoSacubitril/Valsartan | 55 | $65,921 |
| XareltoRivaroxaban | 55 | $49,084 |
| Repatha SureclickEvolocumab | 37 | $32,658 |
| BrilintaTicagrelor | 13 | $15,804 |
| Metoprolol Succinate | 393 | $7,466 |
| Atorvastatin Calcium | 372 | $4,988 |
| Ezetimibe | 118 | $3,480 |
| Amlodipine Besylate | 363 | $2,560 |
| Torsemide | 65 | $2,248 |
| Rosuvastatin Calcium | 164 | $2,230 |
| Potassium Chloride | 55 | $1,643 |
| Carvedilol | 144 | $1,518 |
| Losartan Potassium | 172 | $1,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $396,508318 claims |
| Boehringer IngelheimJardiance | $57 | $77,95355 claims |
| NovartisEntresto | $329 | $65,92155 claims |
| Johnson & JohnsonXarelto | $36 | $49,08455 claims |
| AstraZenecaBrilinta | $145 | $15,80413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Bethlehem
- Luis TejadaBethlehem$78K
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Nainesh PatelAllentown$1.1M
- Jay GiriPhiladelphia$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.